Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib vs BAT in SR-aGvHD
NCT02913261Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised, open-label trial of ruxolitinib in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Novartis. Primary endpoint: Overall Response Rate at 28 days. Started Mar 2017; status: completed.
02
Drugs
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT02913261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02913261.